Fund Radar: Pharma companies regain their growth trajectory

Pharmaceutical companies were once known for their strong growth potential, but slowing revenue growth, lower valuations, and higher dividend yields have given them a more mixed profile in recent years. However, over the past three years, Novo Nordisk and Eli Lilly have stood out by reclaiming their growth status.

The end of the non-dom regime in the United Kingdom

The proposed abolition of the current Non-Dom tax regime marks a significant shift in the UK’s fiscal framework. The new Labour UK government will be taking forward earlier plans to harmonise UK tax resident individuals’ taxation on the basis of their worldwide income and gains, albeit with some modifications.